We tested a way to selectively increase delivery of nano-formulated drugs into solid tumours by disrupting their immature blood vessel system.
In a syngeneic mouse model for TNBC (4T1) we combined
š clinically approved nano-formulated drug
š low-dose small molecule microtubule destabiliser (CA4P)